51 – 60 of 92
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
-
Mark
Body constitution in young healthy women from breast cancer higher risk families in relation to smoking
2017) American Association for Cancer Research (AACR) 108th Annual Meeting 2017 In Cancer Research 77(13).(
- Contribution to journal › Published meeting abstract
- 2016
-
Mark
Heterozygous PINK1 p.G411S mutation increases risk for Parkinson's disease (PD)
2016) 20th International Congress of Parkinson's Disease and Movement Disorders In Movement Disorders 31(Suppl. S2). p.282-282(
- Contribution to journal › Published meeting abstract
-
Mark
Ventricular kinetic energy in young fontan patients
2016) 50th Annual Meeting of the Association for European Paediatric and Congenital Cardiology In Cardiology in the Young 26(Suppl 1). p.64-64(
- Contribution to journal › Published meeting abstract
-
Mark
Hand eczema in healthcare workers : a questionnaire survey of risk factors and work-related exposures
(
- Contribution to journal › Published meeting abstract
-
Mark
Outpatient comprehensive geriatric assessment: Effects on frailty
(
- Contribution to journal › Published meeting abstract
-
Mark
New contact allergens are formed during vulcanization of rubber
2016) 13th Congress of the European Society of Contact Dermatitis In Contact Dermatitis 75(S1). p.44-44(
- Contribution to journal › Published meeting abstract
-
Mark
Global binding pattern of the Wilms' tumor gene 1 (WT1) +17AA -KTS isoform in leukemic cells
2016) American Association for Cancer Research (AACR) 107th Annual Meeting 2016 In Cancer Research 76(14 Suppl.).(
- Contribution to journal › Published meeting abstract
-
Mark
Development after pediatric brain tumor-a longitudinal study
(
- Contribution to journal › Article
-
Mark
The genetic architecture of type 2 diabetes
(
- Contribution to journal › Article
-
Mark
Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: Raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART
(
- Contribution to journal › Article